Academic Journal
Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors
| العنوان: | Bone metastasis in differentiated thyroid cancer: Spanish multicenter study of clinical characteristics, survival and prognostic factors |
|---|---|
| المؤلفون: | Suset Dueñas-Disotuar, Ana Piñar-Gutiérrez, Irene de Lara-Rodríguez, Julia Sastre-Marcos, Emma Anda-Apiñániz, Amelia Oleaga-Alday, JC Galofré, Aida Orois, Victoria Alcázar-Lázaro, Laia Martínez-Guasch, Cecilia Sánchez-Ragnarsson, María Ángeles Gálvez-Moreno, Cristina Familiar-Casado, Tomás Martín-Hernández, Ana R. Romero-Lluch |
| المصدر: | Frontiers in Endocrinology, Vol 15 (2024) |
| بيانات النشر: | Frontiers Media S.A. |
| سنة النشر: | 2024 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | thyroid cancer, bone metastases, survival, skeletal-related events, radioiodine, multikinase inhibitors, antiresorptive agents, Diseases of the endocrine glands. Clinical endocrinology, RC648-665 |
| الوصف: | ObjectiveThis study describes the characteristics, survival and prognostic factors in a cohort of patients with bone metastases (BM) from differentiated thyroid carcinoma (DTC).MethodsThis was a multicenter retrospective observational study conducted in Spain, including patients diagnosed with DTC and BM between 1980 and 2022. A Cox regression analysis was performed to examine prognostic factors for survival. Kaplan-Meier and log-rank tests were performed for survival analysis and comparison between groups.ResultsA total of 133 patients were included with a median follow-up of 40 (17-70) months. Seventy patients (52.6%) had BM at the initial diagnosis. Fifty-two (39.1%) had follicular carcinoma. Sixty-six (49.6%) presented multiple BM. The most frequent location was the spine (63.2%). Other metastases were present at diagnosis in 88 (66.2%), mainly lung (60.9%). BM were treated with I131 in 91 (68.4%) patients, with BM uptake in 63 (47.4%). Fifty-six (42.1%) received treatment with multikinase inhibitors. Fifty-three (3.9%) had skeletal-related events. Seventy-two (54.1%) died. The 3-, 5- and 10-year survival was 53.5, 39.5% and 28.5%, respectively. Significant prognostic factors in the multivariate analysis were the presence of lymph node metastases (N1) HR 1.71 (95% CI 1.005-2.098; p=0.048), BM treatment with I131 HR 0.532 (95% CI 0.304-0.931; p=0.027) and age ≥67 years at BM diagnosis HR 1.991 (95% CI 1.142-3.47; p=0.015).ConclusionsSurvival of DTC patients with BM treated in a Spanish cohort was 39.5% at 5 years and 28.5% at 10 years. Patients with BM treated with I131 appear to have a better outcome in terms of mortality and the presence of lymph node involvement and age over 67 years were associated with higher mortality. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1466245/full; https://doaj.org/toc/1664-2392; https://doaj.org/article/2e647576dfab4b04b1e56969f2f80754 |
| DOI: | 10.3389/fendo.2024.1466245 |
| الاتاحة: | https://doi.org/10.3389/fendo.2024.1466245 https://doaj.org/article/2e647576dfab4b04b1e56969f2f80754 |
| رقم الانضمام: | edsbas.A1FE5547 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3389/fendo.2024.1466245 |
|---|